HLSC 3P21 Chapter Notes - Chapter 15: Compulsory License, Pharmaceutical Manufacturing, Royalty Payment
2 Mar 2017
School
Department
Course
Professor
Document Summary
Amended patent act to extend period of patient exclusivity for new pharmaceuticals in. Canada from 17 to 20 years and eliminate compulsory licensing. Pitted social goals (and the interested of those using and paying for drugs) against economic goals (and interests of those developing and selling these products) Bill c-91 introduced to amend the patent act: because of this, 24,000 canadians were employed by the pharmaceutical company (research or marketing) Intellectual property (ip) - intangible creations and inventions: creators have exclusive right over its use. There is no requirement for provincial insurance plans to cover drug costs unless administered in a hospital. Some provincial governments voluntarily implemented drug programs for certain populations (those who are eligible by age, income, disease) There is also private insurance coverage for pharmaceuticals. History of federal legislation on pharmaceutical patent protection. 1969 policy changed: generic drug companies permitted to import pharmaceutical compounds as long as paid a 4% royalty fee to patent colder, more successful!
